Genomic Health (GHDX) Earns Daily News Impact Score of 0.13
News stories about Genomic Health (NASDAQ:GHDX) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genomic Health earned a news impact score of 0.13 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.2084825595032 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Genomic Health (GHDX) traded up 1.85% during midday trading on Wednesday, reaching $32.54. The company’s stock had a trading volume of 113,171 shares. Genomic Health has a 52 week low of $26.37 and a 52 week high of $33.97. The firm’s market capitalization is $1.13 billion. The stock has a 50 day moving average of $31.42 and a 200 day moving average of $31.64.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The firm had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.18) earnings per share. On average, equities research analysts predict that Genomic Health will post ($0.02) earnings per share for the current fiscal year.
Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Cowen and Company restated a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a report on Friday, September 1st. Jefferies Group LLC restated a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a report on Thursday, September 14th. Canaccord Genuity restated a “buy” rating and set a $35.00 price objective on shares of Genomic Health in a report on Wednesday, September 27th. Finally, BidaskClub downgraded Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. Genomic Health currently has an average rating of “Hold” and a consensus target price of $31.83.
TRADEMARK VIOLATION WARNING: “Genomic Health (GHDX) Earns Daily News Impact Score of 0.13” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/11/genomic-health-ghdx-earns-daily-news-impact-score-of-0-13.html.
In other news, insider James J. Vaughn sold 8,000 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total value of $244,720.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $31.93, for a total value of $159,650.00. The disclosure for this sale can be found here. In the last three months, insiders sold 36,174 shares of company stock worth $1,129,171. 46.20% of the stock is currently owned by company insiders.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.